Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced that the clinical research results of CS2009 (PD-1/VEGF/CTLA-4 three specific antibodies), one of the company's core assets, were successfully selected for the 2026 European Society of Medical Oncology (ESMO) annual meeting, and will be presented in the form of two quick oral reports, covering phase I/II clinical trial data of CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.